Mannitol Dosing for Acute Intracranial Hemorrhage with Increased ICP
For adults with acute intracranial hemorrhage and signs of increased intracranial pressure, administer mannitol 20% at a dose of 0.25-1 g/kg IV over 15-20 minutes, with larger doses (0.5-1 g/kg over 15 minutes) appropriate for acute intracranial hypertensive crisis. 1
Recommended Dosing Protocol
Initial Bolus Dose
- Standard dose: 0.25-1 g/kg of 20% mannitol IV over 15-20 minutes 1
- Acute crisis dose: 0.5-1 g/kg over 15 minutes for threatened herniation or acute intracranial hypertensive crisis 2, 1
- Alternative dosing: 0.25-2 g/kg as 15-25% solution over 30-60 minutes 3
The 2018 Anaesthesia guidelines provide the most specific recommendation, stating mannitol should be given at an equiosmotic dose of approximately 250 mOsm over 15-20 minutes 1. This represents a Grade 1+ recommendation with strong agreement for treating threatened intracranial hypertension or signs of brain herniation 1.
Maintenance Dosing
- Repeat doses: 0.25-1 g/kg every 4-6 hours as needed 4
- Monitor serum osmolality every 6 hours; hold if ≥320 mOsm/kg or osmolality gap ≥40 4
- Maximum total dose: 2 g/kg 5
Research demonstrates that smaller, more frequent doses (every 4 hours) are more effective than larger, less frequent doses in the first 4 days after hemorrhage 6. The effect of mannitol is dose-dependent during the ICP reduction phase but not after ICP stabilizes 7.
Administration Guidelines
Infusion Rate and Timing
- Administer over 15-20 minutes for acute intracranial hypertension 1
- Maximum effect occurs at 10-15 minutes, lasting 2-4 hours 1
- Evidence of ICP reduction should be observed within 15 minutes 3
Monitoring Requirements
- Place urinary catheter before administration 2
- Check serum osmolality and metabolic profile every 6 hours 4
- Monitor fluid balance, sodium, and chloride levels 1
- Discontinue if serum osmolality exceeds 320 mOsm/kg 4
The FDA label specifies that careful evaluation of circulatory and renal reserve must be made before and during administration, with attention to fluid and electrolyte balance, body weight, and total input/output 3.
Critical Considerations
Dose-Response Relationship
Research shows that ICP reduction is proportional to baseline ICP values, with approximately 0.64-0.66 mmHg decrease for each 1 mmHg increase in initial ICP 8. The effect is also influenced by hemorrhage location (supratentorial vs. infratentorial) and hematoma volume 7. Smaller doses (0.25 g/kg) can be as effective as larger doses (0.5-1 g/kg) for acute ICP reduction 9, 10.
Comparison with Hypertonic Saline
At equiosmotic doses (approximately 250 mOsm), mannitol and hypertonic saline have comparable efficacy 1. However, a 2011 meta-analysis suggested hypertonic saline may be more effective than mannitol for acutely elevated ICP 11. Mannitol uniquely improves cerebral oxygenation compared to other ICP-lowering therapies 1.
Contraindications and Precautions
- Absolute contraindications: well-established anuria, severe pulmonary edema, active intracranial bleeding (except during craniotomy), severe dehydration, progressive heart failure 3
- Avoid in patients with impaired autoregulation, as lower CPP targets (60 mmHg) may be preferable 1
- Do not use prophylactically in patients without evidence of intracranial hypertension 1
Side Effects
Mannitol induces osmotic diuresis requiring volume compensation, while avoiding hypovolemia and hyperosmolar states 1. The risk of renal failure increases with pre-existing renal disease, concomitant nephrotoxic drugs, or other diuretics 3.
Adjunctive Measures
Mannitol should be used in conjunction with other ICP management strategies: 2
- Head-of-bed elevation to 20-30 degrees 5, 4
- Sedation and analgesia
- Cerebrospinal fluid drainage if ventriculostomy present 12
- Avoidance of hypoxemia, hypercarbia, and hyperthermia 5
- Maintenance of cerebral perfusion pressure 60-70 mmHg 1
Avoid prolonged hyperventilation (PaCO2 <30 mmHg) as it worsens neurological outcomes 1.
Duration of Therapy
Research suggests mannitol should not be used for more than 8 days, with the most effective period being the first 4-5 days after hemorrhage 6. After the 5th day, use should be guided by ICP measurements rather than scheduled dosing 6.